Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Heath

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Abdominal Radiology (New York)|April 7, 2025
Fast prostate MRI vs. conventional multiparametric prostate MRI: comparison and outcomesHamed Kordbacheh, Gorica Ristic, Elisabeth Heath, et al.
American Journal of Therapeutics|January 29, 2008
Lycopene in cancer prevention and treatmentSoley Seren, Ronald Lieberman, Ulas D Bayraktar, et al.
The Prostate|October 14, 2014
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genesDejuan Kong, Seema Sethi, Yiwei Li, et al.
Molecular Pharmacology|July 7, 2016
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer CellsRayna Rosati, Bailing Chen, Mugdha Patki, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 15, 2016
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With CancerLauren M Hamel, Louis A Penner, Terrance L Albrecht, et al.
Anti-Cancer Drugs|July 30, 2011
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunctionSachin Gupta, Venkata Parsa, Lance K Heilbrun, et al.
Molecular Cancer Research : MCR|May 31, 2011
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cellsXiaohua Li, Alexander Kaplun, Fulvio Lonardo, et al.
Patient Education and Counseling|January 17, 2025
From community to scale: Using community engagement to develop and validate a patient-informed cancer communication scaleLauren M Hamel, Diliara Bagautdinova, Bill Winkler, et al.
Urologic Oncology|February 26, 2013
Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancerUlka N Vaishampayan, Joseph Fontana, Lance K Heilbrun, et al.
HGG Advances|April 24, 2026
Characterization of Von Hippel Lindau Gene Variants in an African American CohortYusra F Shao, Diana Duque, Abdul-Rahman Alloghbi, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Abdominal Radiology (New York)|April 7, 2025
Fast prostate MRI vs. conventional multiparametric prostate MRI: comparison and outcomesHamed Kordbacheh, Gorica Ristic, Elisabeth Heath, et al.
American Journal of Therapeutics|January 29, 2008
Lycopene in cancer prevention and treatmentSoley Seren, Ronald Lieberman, Ulas D Bayraktar, et al.
The Prostate|October 14, 2014
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genesDejuan Kong, Seema Sethi, Yiwei Li, et al.
Molecular Pharmacology|July 7, 2016
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer CellsRayna Rosati, Bailing Chen, Mugdha Patki, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 15, 2016
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With CancerLauren M Hamel, Louis A Penner, Terrance L Albrecht, et al.
Anti-Cancer Drugs|July 30, 2011
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunctionSachin Gupta, Venkata Parsa, Lance K Heilbrun, et al.
Molecular Cancer Research : MCR|May 31, 2011
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cellsXiaohua Li, Alexander Kaplun, Fulvio Lonardo, et al.
Patient Education and Counseling|January 17, 2025
From community to scale: Using community engagement to develop and validate a patient-informed cancer communication scaleLauren M Hamel, Diliara Bagautdinova, Bill Winkler, et al.
Urologic Oncology|February 26, 2013
Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancerUlka N Vaishampayan, Joseph Fontana, Lance K Heilbrun, et al.
HGG Advances|April 24, 2026
Characterization of Von Hippel Lindau Gene Variants in an African American CohortYusra F Shao, Diana Duque, Abdul-Rahman Alloghbi, et al.
Pageof 7